how to administer semaglutide at home Give Yourself a Shot of Semaglutide: Complete Guide How to Administer Your Own

Another systematic review found that people were able to maintain weight loss when they took a GLP-1 for two years or more

While there isnt definitive research on this for nasal administration, some protocols suggest using it away from meals to avoid any potential interference with absorption

Its a fitter, more energetic you with a body thats leaner and stronger

Weeks 3 to 4 represent the highest risk for blood sugar elevation as tirzepatide clears before semaglutide reaches full effect

Study Snapshot Design: Randomized, double-blind, placebo-controlled trial Duration: 26 weeks Population: Treatment-seeking adults with AUD + obesity Completers: 88 participants Intervention: Once-weekly semaglutide + behavioral therapy Funding: Novo Nordisk Foundation Key Findings (Simplified) Heavy drinking days significantly reduced ~41% reduction with semaglutide vs ~26% placebo Treatment effect difference: ~13.7% improvement vs placebo Absolute reduction: ~12 fewer heavy drinking days/month (vs ~8 days in placebo) Alcohol-Related Outcomes Total alcohol intake Frequency of binge/heavy drinking episodes Alcohol craving (supported by prior trials) Biomarker-confirmed reductions in alcohol exposure Metabolic & Somatic Benefits Significant weight loss Improved blood pressure & cardiometabolic profile Reinforces dual benefit: metabolic + behavioral modulation Mechanistic Insight (Emerging) GLP-1 receptor agonists may: Modulate reward pathways Reduce dopamine-driven craving signals Decrease cue-induced alcohol seeking behavior Important Limitations Small sample size (n=88 completers) Conducted in motivated, treatment-seeking population Combined with cognitive behavioral therapy (not drug-only effect) No long-term post-treatment follow-up Why This Matters AUD remains under-treated globally Current pharmacotherapies have limited uptake & modest efficacy Semaglutide introduces a novel, biologically plausible pathway Potential shift toward metabo-psychiatric therapeutics Clinical Takeaway This is not just a weight-loss drug anymore It may represent a new frontier in addiction medicine But: Larger, real-world trials are essential before routine clinical adoption